Levofloxacin Shortage: What Providers and Prescribers Need to Know in 2026

Levofloxacin has been a workhorse antibiotic for decades — treating everything from community-acquired pneumonia to complicated UTIs and prostatitis. But the drug's intravenous (IV) formulation is currently listed on the ASHP Drug Shortage Database, and prescribers are managing these supply constraints in hospital and institutional settings across the country.

This clinical briefing provides a current snapshot of the shortage, its supply chain causes, therapeutic alternatives by indication, antimicrobial stewardship considerations, and practical tools to help your patients access levofloxacin when it is the appropriate choice.

Current Supply Status (Updated April 2026)

The shortage specifically affects levofloxacin injection in 5% dextrose (premixed IV bags):

• Hikma: 500 mg/100 mL on back order; estimated release late-April to early-May 2026. The 250 mg/50 mL and 750 mg/150 mL bags are on back order with no estimated release date.
• Baxter: Has discontinued all levofloxacin premixed bag products.
• Available manufacturers: Pfizer (250 mg/50 mL, 500 mg/100 mL, 750 mg/150 mL), Sagent (250 mg/50 mL, 500 mg/100 mL), and WG Critical Care have supply available, providing partial market coverage.
• Oral formulations: Not in national shortage. Oral tablets (250 mg, 500 mg, 750 mg) and oral solution (25 mg/mL) are generally available at retail pharmacies.

Supply Chain Drivers

Several structural factors are driving this shortage:

• Market consolidation: The premixed IV antibiotic bag market is served by a small number of manufacturers. Baxter's exit from this product line removed a major supply pillar and concentrated demand on remaining suppliers.
• Sterile manufacturing complexity: IV solutions require aseptic manufacturing conditions subject to FDA scrutiny. Production capacity cannot be ramped up quickly.
• Generic market economics: Thin margins on generic IV products reduce the economic incentive for manufacturers to maintain excess capacity as a buffer.

Clinical Implications: Affected Indications

Levofloxacin IV is commonly used for:

• Community-acquired pneumonia (CAP) — including severe and ICU-level CAP
• Hospital-acquired (nosocomial) pneumonia
• Complicated urinary tract infections and pyelonephritis
• Skin and soft tissue infections
• Anthrax and plague treatment and prophylaxis

Therapeutic Alternatives by Indication

For Community-Acquired Pneumonia (CAP):

• Moxifloxacin 400 mg IV/PO once daily — enhanced gram-positive and atypical coverage; no dose adjustment for renal impairment
• Beta-lactam (ceftriaxone 1-2 g IV daily) + macrolide (azithromycin 500 mg IV/PO daily) — IDSA/ATS guideline-concordant for most CAP
• Ciprofloxacin 400 mg IV q8-12h — adequate for gram-negatives but limited gram-positive activity

For Complicated UTI/Pyelonephritis:

• Ciprofloxacin 400 mg IV q8-12h — widely available, well-studied for UTI
• Ceftriaxone 1-2 g IV daily — preferred if susceptibility data support; step-down to oral TMP-SMX or nitrofurantoin per sensitivities
• Ertapenem 1 g IV daily — for ESBL-producing organisms where fluoroquinolones are inappropriate

IV-to-Oral Step-Down: A Key Management Strategy

Levofloxacin has excellent oral bioavailability (approximately 99%), making IV-to-oral step-down clinically appropriate once a patient meets stability criteria. During a shortage, early step-down to oral levofloxacin tablets — which are not affected by the shortage — is an effective conservation strategy that maintains therapeutic coverage without requiring the scarce IV product.

Step-down criteria typically include: tolerating oral medications, improving clinical signs, afebrile x 24 hours, and white blood cell count trending toward normal.

Antimicrobial Stewardship Considerations

The shortage creates an opportunity for stewardship reinforcement:

• Reserve IV levofloxacin for patients who cannot absorb oral medications or have severe infections requiring IV administration
• Perform early step-down to oral levofloxacin or appropriate alternatives based on culture and sensitivity data
• Ensure culture specimens are obtained before initiating therapy to allow de-escalation when possible
• Avoid prophylactic use of IV levofloxacin in non-high-risk patients during the shortage period

Helping Patients Access Oral Levofloxacin at Retail Pharmacies

For patients discharged on oral levofloxacin or those receiving outpatient prescriptions, pharmacy stocking gaps can occasionally occur. Direct patients to medfinder.com/providers — a tool that calls pharmacies in the patient's area to find which ones can fill their specific prescription. This eliminates the burden of patients making dozens of calls themselves, which is particularly helpful for patients who are ill and don't have the capacity for extended phone searches.

Summary for Prescribers

• IV levofloxacin (premixed bags): active shortage; multiple manufacturers affected; Pfizer, Sagent, WG Critical Care have limited supply
• Oral levofloxacin: not in shortage; 99% bioavailability makes it an excellent step-down option
• Key alternatives: moxifloxacin (respiratory), ciprofloxacin (UTI, gram-negative), ceftriaxone + azithromycin (CAP)
• Prioritize early IV-to-oral step-down and culture-based de-escalation to conserve IV supply
• Direct discharged patients to medfinder.com for outpatient pharmacy access support